Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Oligodendroglioma × Radiation × Clear all

Phase

Status

Sponsor Class

OTHER 3 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 16 Carcinoma, Non-Small-Cell Lung 6 Brain Neoplasms 5 Head and Neck Neoplasms 4 Neoplasms 3 Neoplasm Metastasis 3 Melanoma 3 Glioma 3 Esophageal Neoplasms 3 Carcinoma, Squamous Cell 3 Breast Neoplasms 3 Stomach Neoplasms 2 Sarcoma 2 Prostatic Neoplasms 2 Pain 2 Lung Neoplasms 2 Gliosarcoma 2 Central Nervous System Neoplasms 2 Bone Neoplasms 2 Astrocytoma 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Stomatitis 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neuroectodermal Tumors 1 Nervous System Diseases 1 Neoplasms by Site 1

Interventions

Temozolomide 4 Flucytosine 4 vocimagene amiretrorepvec 3 vorasidenib 2 trametinib 2 paclitaxel-Angiopep-2 conjugate 2 dabrafenib 2 OKN 007 2 Chlorotoxin 2 Carmustine 2 talampanel 1 selinexor 1 pemigatinib 1 pembrolizumab 1 olutasidenib 1 motexafin gadolinium 1 exatecan 1 Vincristine 1 Surgical Procedures, Operative 1 Radiation 1 PF-06840003 1 ONC206 1 O(6)-benzylguanine 1 Metabolism 1 Genetic Therapy 1 Genetic Engineering 1 Filgrastim 1 Fentanyl 1 Carboplatin 1 BID protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02871843 2022-05-16

G-FORCE-1

EpicentRx, Inc.

Phase 1 Completed

Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡